abbott diabetics

Quote

anonymous said:
Says the Abbott sales rep. Hahahahaha
Click to expand...

No...not a sales rep. A chemist and engineer. I worked at ADC for awhile and saw the Libre development. After leaving Abbott I have followed the progress of CGM. Abbott did the first low cost CGM. DexCom is trying to do the same. As I said previously the G7 is behind but it will get there at some point. Then patients can choose between Libre 3 and G7.
 








anonymous said:
No...not a sales rep. A chemist and engineer. I worked at ADC for awhile and saw the Libre development. After leaving Abbott I have followed the progress of CGM. Abbott did the first low cost CGM. DexCom is trying to do the same. As I said previously the G7 is behind but it will get there at some point. Then patients can choose between Libre 3 and G7.
Click to expand...

I would think a chemist & engineer would know the difference between "awhile" & "a while", and that "a while" is the correct choice consdering the placement after a preposition..
 
















anonymous said:
Dexcom's G7 is delayed by 2 years - it is not working, leaking moisture, and they can't get the design right. Even when it does come out at scale (4Q 2023) it is still larger than Libre 2 and unwieldy. G7 is no threat to ADC.
Click to expand...

I can vouch for that as a Dexcomer (soon to be ex-Dexcomer as I am on my way out for another med device company in Q4); I was with ADC a few years back before going to Dexcom. Abbott knows NPI & Scaling well. Dexcom has some creative types who put out innovative designs, but with G7, those designs are failing - G7 is now 18 months behind schedule.
 








anonymous said:
I can vouch for that as a Dexcomer (soon to be ex-Dexcomer as I am on my way out for another med device company in Q4); I was with ADC a few years back before going to Dexcom. Abbott knows NPI & Scaling well. Dexcom has some creative types who put out innovative designs, but with G7, those designs are failing - G7 is now 18 months behind schedule.
Click to expand...

I can believe this. As I mentioned before the strength of ADC's Libre system is the sensor designed by Dr. Ben. It has been around since 1999 and ADC has a lot of experience with the technology. The G6 sensor is very good but does not lend itself to a small, inexpensive on body device. So DexCom had to start over for the G7. What I find interesting is that Abbott announced the Libre 3 back in Sept of 2020 but is only selling it in Germany. Not a big rollout. I am assuming ADC is having quality issues with Libre 3.
 
















anonymous said:
Well us sales peeps do pay your salary you know. Lol
Click to expand...

And the sales peeps need something to sell. Back in 2008 ADC was losing market share on meters and strips. The competition had caught up. R&D was asked to find something new. Later that year the second Nav CGM system was finished by the CGM team. Based on that system the folks in that team came up with the idea of Libre...glucose on demand. This was a team effort involving all parts of the company. It took the efforts of everyone to create the current ADC success story. Revenue in 2009 was less than $1B. Now it's at about $3.5B......again a team effort.
 








anonymous said:
And the sales peeps need something to sell. Back in 2008 ADC was losing market share on meters and strips. The competition had caught up. R&D was asked to find something new. Later that year the second Nav CGM system was finished by the CGM team. Based on that system the folks in that team came up with the idea of Libre...glucose on demand. This was a team effort involving all parts of the company. It took the efforts of everyone to create the current ADC success story. Revenue in 2009 was less than $1B. Now it's at about $3.5B......again a team effort.
Click to expand...

ADC always tries to hang their hats on technology. Endo’s don’t give 2 shits about technology. All they want to see is a glucose # and they don’t care how the patient has to get it. Also they know a glucose # is a glucose # whether it’s an old school finger stick or a fancy expensive CM.
 








anonymous said:
ADC always tries to hang their hats on technology. Endo’s don’t give 2 shits about technology. All they want to see is a glucose # and they don’t care how the patient has to get it. Also they know a glucose # is a glucose # whether it’s an old school finger stick or a fancy expensive CM.
Click to expand...

Not true for two reasons. First if a person is T1 they need to test a lot so the cost of strips for some of these patients is high. Not as high as a modern CGM but close. The second if even if a patient tests 10 times a day (bad for the fingers) the amount of data pales to the over 100 tests or more from a CGM. Most diabetics test less than 10 times a day. The more data the Endo has the better he/she can determine the health of the patient. Also the cost of CGMs is going down. The overall cost is more than strips and meters but the cost per data point is less.
 








Dexcom is not as bad as Theranos - there are real revenues and profits at Dexcom; just not what is being reproted by QB; numbers are being inflated 3-fold. Also, Dexcom is suing Abbott for IP Theft - but Dexcom is no match for Abbott's corporate legal might
 








































Good for them.... There are more important things in this world than money . I'd rather sell a superior product for less money than make more selling the #2 CGM. But hey that's just me.... some people are in this for the money. I've been there done that and I'm much happier now.
 
















anonymous said:
Good for them.... There are more important things in this world than money . I'd rather sell a superior product for less money than make more selling the #2 CGM. But hey that's just me.... some people are in this for the money. I've been there done that and I'm much happier now.
Click to expand...

Really? More important things than money you say? Tell the Abbott share holders that and they’ll shoot you between the eyes Mr Chemist. The company is ALL about the money but they chose not to share it with the reps. Greedy Bastards.
 








anonymous said:
Really? More important things than money you say? Tell the Abbott share holders that and they’ll shoot you between the eyes Mr Chemist. The company is ALL about the money but they chose not to share it with the reps. Greedy Bastards.
Click to expand...

This is the Chemist. I did not post this...money is important. I never made it to the 1% but got to the 2.7%. Not bad for the poor kid who had no college fund. Worked my way though.

Does anybody know when Libre 3 will out in the EU? I know it is in Germany (a pilot release). Is ADC having initial production problems as they did with Libre 1?
 
















anonymous said:
Not in cash; Dx gives out more RSUs across the board than ADC; however, there is a catch - Dx fires many employees before their RSUs can fully vest in 3-4 years. That's the Dx-CFO (QB's) way of luring in hig-performers without parting with hard cash.
Click to expand...

Typical behavior of the dishonorable. He does this often enough prospective employees read about it, as on this board, and they will not hire in..
 








Top Bottom
Back
Quote